Skip Navigation


JAC Advance Access originally published online on December 12, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/1/171    most recent
dkg045v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bongiovanni, M.
Right arrow Articles by d’Arminio Monforte, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bongiovanni, M.
Right arrow Articles by d’Arminio Monforte, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 171-174
© 2003 The British Society for Antimicrobial Chemotherapy

Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study

Marco Bongiovanni, Teresa Bini*, Federica Tordato, Paola Cicconi, Sara Melzi, Dolores Repetto, Salvatore Sollima, Stefano Rusconi and Antonella d’Arminio Monforte

Institute of Infectious and Tropical Diseases, University of Milan, Luigi Sacco Hospital, via G.B. Grassi 74, 20157 Milan, Italy

Received 8 April 2002, returned 2 July 2002, revised 1 August 2002; accepted 20 August 2002

The immunovirological outcome of lopinavir/ritonavir was evaluated in 70 antiretroviral-experienced HIV patients; at baseline, median CD4+ cell count was 218 cells/mm3 and median plasma viraemia 4.58 log10 copies/mL. After 12 months, we observed an increase in CD4+ cell count to 322 cells/mm3 (P = 0.0001) and a decrease in plasma viraemia to 2.35 log10 copies/mL (P = 0.0001). Four patients discontinued lopinavir/ritonavir during observation. Among metabolic parameters, only triglyceride concentrations increased during treatment (P = 0.02). Twenty-six patients had a genotypic resistance test at baseline; four had >=6 mutations known to reduce susceptibility to lopinavir/ritonavir. Undetectable plasma viraemia was obtained only in patients with <=5 mutations (61.9%).

* Corresponding author. Tel: +39-02-3904-2677; Fax: +39-02-356-0805; E-mail: tbini{at}mailserver.unimi.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
B. Larru, S. Resino, J. M. Bellon, M. I. de Jose, C. Fortuny, M. L. Navarro, M. D. Gurbindo, J. T. Ramos, P. Soler Palacin, J. A. Leon, et al.
Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children
J. Antimicrob. Chemother., January 1, 2008; 61(1): 183 - 190.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.